Posted by Michael Wonder on 18 Sep 2025
Alteogen receives European Commission approval for aflibercept biosimilar, Eyluxvi (ALT-L9)
17 September 2025 - Eyluxvi is the second biosimilar approved for Alteogen following the launch of the Herceptin biosimilar in China through its partner Qilu Pharmaceutical.
Alteogen announced today that the European Commission has granted marketing authorization for Eyluxvi (ALT-L9), an Eylea biosimilar co-developed by its subsidiary, Alteogen Biologics.
